Promega is launching the TarSeer BRETSA Target Engagement System, a live-cell, target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins, the company announced recently.

“You can now potentially study intracellular target engagement for any protein in live cells,” Promega Associate Director of R&D Matt Robers said in a statement. “This platform will give drug discovery researchers new starting points to go after a huge fraction of previously intractable therapeutic targets within the human proteome.”

According to a release, the TarSeer BRETSA Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation.

The platform will be previewed at the Society for Laboratory Automation and Screening (SLAS) International Conference Exhibition this week.